Anthrax countermeasures: current status and future needs.

The U.S. government does not yet have the range of medical countermeasures needed to protect its citizens from anthrax and other potential bioweapons. In the event of an anthrax attack, treatment interventions in addition to antibiotics would be needed so that very ill patients can be treated and clean-up crews can be better protected, especially if an engineered strain is used. This article describes specific anthrax countermeasures that are in development, barriers to development, and potential mechanisms the government could use to accelerate the movement of these countermeasures through the pipeline. A key challenge will be to encourage the transition of promising leads from basic research to the product development stage, when they may qualify for BioShield funds.

[1]  A. Athamna,et al.  In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. , 2004, The Journal of antimicrobial chemotherapy.

[2]  Thomas V Inglesby,et al.  Biodefense R&D: anticipating future threats, establishing a strategic environment. , 2003, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[3]  Iain McLean,et al.  State of the Union , 2005 .

[4]  Ari Schuler,et al.  Taking the measure of countermeasures: leaders' views on the nation's capacity to develop biodefense countermeasures. , 2004, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[5]  John Travis.  Interview with Michael Goldblatt, Director, Defense Sciences Office, DARPA , 2003 .

[6]  R. Brookmeyer,et al.  The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. , 2001, Biostatistics.

[7]  D. Kobiler,et al.  Postexposure Prophylaxis against Anthrax: Evaluation of Various Treatment Regimens in Intranasally Infected Guinea Pigs , 2002, Infection and Immunity.

[8]  A. Athamna,et al.  Selection of Bacillus anthracis isolates resistant to antibiotics. , 2004, The Journal of antimicrobial chemotherapy.

[9]  B. Ivins,et al.  Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. , 2001, Vaccine.

[10]  Elizabeth R. Zell,et al.  Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence , 2002, Emerging infectious diseases.

[11]  Anthony S. Fauci,et al.  Biodefence on the research agenda , 2003, Nature.

[12]  L. Grummer-Strawn,et al.  Adherence to Antimicrobial Inhalational Anthrax Prophylaxis among Postal Workers, Washington, D.C., 2001 , 2002, Emerging infectious diseases.

[13]  R. Brookmeyer,et al.  Public health vaccination policies for containing an anthrax outbreak , 2004, Nature.

[14]  Ken Alibek,et al.  Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World--Told from the Inside by the Man Who Ran It , 1999 .

[15]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.